Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of CJ-30060 vs Exforge + Crestor in Healthy Volunteers
NCT03757390Phase 1Unknown
- Sponsor
- HK inno.N Corporation
- Start
- Nov 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CJ-30060 in hypertension (HTN) and hyperlipidemia (2 arms), sponsored by HK inno.N Corporation. Primary endpoints: Peak Plasma Concentration (Cmax) up to 72 hours and Area Under the Curve to the Last Quantifiable Concentration (AUClast) up to 72 hours. Status: unknown.
02
Drugs
CJ-30060
03
Conditions
hypertension (HTN)hyperlipidemia
Beyond the preview
Go deeper on NCT03757390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03757390.